TrianglePUBLICATIONS · 38857463
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2024 Oct 20
- First author
- Leighl NB
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Leighl NB
- type
- Author
- name
- Akamatsu H
- type
- Author
- name
- Lim SM
- type
- Author
- name
- Cheng Y
- type
- Author
- name
- Minchom AR
- type
- Author
- name
- Marmarelis ME
- type
- Author
- name
- Sanborn RE
- type
- Author
- name
- Chih-Hsin Yang J
- type
- Author
- name
- Liu B
- type
- Author
- name
- John T
- type
- Author
- name
- Massutí B
- type
- Author
- name
- Spira AI
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Leighl NB
- type
- Author
- name
- Akamatsu H
- type
- Author
- name
- Lim SM
- type
- Author
- name
- Cheng Y
- type
- Author
- name
- Minchom AR
- type
- Author
- name
- Marmarelis ME
- type
- Author
- name
- Sanborn RE
- type
- Author
- name
- Chih-Hsin Yang J
- type
- Author
- name
- Liu B
- type
- Author
- name
- John T
- type
- Author
- name
- Massutí B
- type
- Author
- name
- Spira AI
- type
- Author
- bibliography ids
- nci-bib-08ee6080e6f2bc9ac1e06fdd
- book metadata
- content sha256
- ada8f574f5ab3d1b4dc4a983a3eb10b3fb5ec937ed31306dc1f31d8e819a28b3
- document type
- citation
- dois
- 10.1200/JCO.24.01001
- electronic publication date
- display
- 2024 Jun 10
- precision
- day
- year
- 2024
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:38857463
- immutable id
- pubmed:38857463@ada8f574f5ab3d1b4dc4a983a3eb10b3fb5ec937ed31306dc1f31d8e819a28b3
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- 1527-7755
- issn print
- 0732-183X
- issue
- 30
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 3593-3605
- volume
- 42
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 38857463
- provenance
- batch id
- 3e43afde6f26fc8df6da
- provider
- NCBI PubMed ESummary
- record sha256
- fd63fe82bf5be9a6a24b579ac5134e1942c26500baf5add9f443224a4a4b4fd8
- response sha256
- fa51c3b310a444d84ada833c4cda53c9e4e97161ab5048020b99c51e56e843d2
- retrieved at
- 2026-09-09T23:48:21.145285+00:00
- publication date
- display
- 2024 Oct 20
- precision
- day
- year
- 2024
- publication types
- Journal Article
- Clinical Trial, Phase III
- Randomized Controlled Trial
- Multicenter Study
- Comparative Study
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.
Preserved source evidence · Not medical advice